Metastatic Breast Cancer Survey - Piqray (alpelisib)

Rethink Breast Cancer is looking for postmenopausal women, and men, with HR-positive, HER2-negative, metastatic breast cancer and anyone who has been treated with Piqray (alpelisib) to talk about their experience.

The Canadian Agency for Drugs and Technologies in Health (CADTH) makes recommendations about whether provincial health plans should pay for new cancer drugs. CADTH will soon be reviewing the use of Piqray (alpelisib) in combination with Faslodex (fulvestrant) to treat hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer after disease progression following treatment with an aromatase inhibitor in combination with a CDK4/6 inhibitor.

Rethink Breast Cancer will be making a submission to ensure that patient voices are represented and considered during the review process. We would like to speak with patients about their experience with HR-positive, HER2-negative, metastatic breast cancer.
 
You do not need to live in Canada to respond to this survey; we appreciate input from every patient.

We are also interested in speaking directly with those who have treatment experience with Piqray (alpelisib).

Please contact MJ DeCoteau at survey@rethinkbreastcancer.com if you would be willing to participate in a brief telephone interview.
 
We would like to thank everyone for helping to ensure that patient experiences are represented in the cancer drug funding review process.
 
Privacy Policy: To ensure patient privacy and confidentiality, individual responses will not be identifiable. It is important to note that selected quotations may be used for the final submission to government agencies without reference to patient name or any other information that could lead to identifying the patient.

Question Title

* 1. Have you been diagnosed with HR-positive, HER2-negative, advanced or metastatic breast cancer?

Question Title

* 2. Does your breast cancer include the PIK3CA mutation?

Question Title

* 3. What is your menopausal status

Question Title

* 5. What treatment phase are you in?

Question Title

* 6. What treatments have you received since your diagnosis?

Question Title

* 7. Please describe your overall experience with these cancer treatments including both positive and negative experiences.

Question Title

* 8. What side effects have you experienced as a result of treatment?

Question Title

* 9. If you experienced treatment side effects, which did you find most difficult to tolerate?

Question Title

* 10. Have you had difficulties accessing cancer treatments?

Question Title

* 11. Do you have financial challenges as a result of your breast cancer treatment?

Question Title

* 12. Have you needed financial assistance due to costs associated with breast cancer or its treatment?

Question Title

* 13. On a scale of 1 (not important) to 5 (very important), how important are these outcomes for your breast cancer treatment?

  1 - not important 2 3 4 5 - very important
Controlling disease progression
Reducing symptoms
Maintaining quality of life
Managing side effects
Preventing recurrence

Question Title

* 15. Since your cancer became metastatic, has your doctor spoken with you about genomic testing of your tumour?

Question Title

* 16. If you have received genomic tumour testing, was your tumour tested for the PIK3CA mutation?

Questions 17-31 are for patients with Piqray (alpelisib) treatment experience. If you have not received this treatment, you can proceed directly to Question 32.

Question Title

* 17. Have you been treated as a breast cancer patient with Piqray (alpelisib)?

Question Title

* 18. Did you receive Piqray in combination with Faslodex (fulvestrant)?

Question Title

* 19. Were you treated with an aromatase inhibitor like Femara (lestrozole), Aromasin (exemestane) or Arimidex (anastrozole) prior to receiving Piqray?

Question Title

* 20. Were you treated with a CDK 4/6 inhibitor like Ibrance (palbociclib), Verzenio (abemaciclib) or Kisqali (ribociclib) prior to receiving Piqray?

Question Title

* 21. How long were you treated with Piqray?

Question Title

* 22. Are you still receiving Piqray for treatment of breast cancer?

Question Title

* 23. Did you require any dose reductions during your Piqray treatment? If so, why?

Question Title

* 24. On a scale of 1 (much worse) to 5 (much better), how has your life changed on Piqray compared to other therapies that you received?

  1 - much worse 2 3 4 5 - much better
Controlling disease progression
Metastatic cancer symptoms
Drug side effects
Maintaining quality of life
Preventing recurrence
Ability to work
Ability to sleep
Ability to drive
Ability to perform household chores
Ability to care for children

Question Title

* 25. What side effects have you experienced while on Piqray?

Question Title

* 27. Did you have any difficulty accessing Piqray?

Question Title

* 28. Did having a dedicated treatment option for PIK3CA-mutated breast cancer affect your mental or emotional well-being?

Question Title

* 29. Did your doctor suggest any alternatives if treatment with Piqray was unavailable?

Question Title

* 30. Overall, what has been your experience with Piqray? Describe the positive and negative.

Question Title

* 31. Based on your personal experiences with Piqray, would you recommend it to other patients with breast cancer?

Question Title

* 32. What country are you from?

Question Title

* 34. Would you be willing to participate in a telephone survey to discuss your experience with Piqray?

Question Title

* 35. If yes, please enter your email address or phone number below.

If you have a primary caregiver who is willing to participate in this survey, please allow them to complete the following questions by themselves.

If you don't have a primary caregiver or if they do not wish to participate in this survey, click Done at the bottom of the page to complete the survey.

Question Title

* 36. What is your relationship to the breast cancer patient?

Question Title

* 37. How would you describe the severity of the challenges you have faced as a caregiver on a scale of 1 (not at all severe) to 5 (very severe)? Please elaborate in the comments section.

  1 - not at all severe 2 3 4 5 - very severe
Financial
Health
Educational
Social
Professional

Question Title

* 38. What type of support is or would be most helpful for you in order to care for someone with breast cancer?

Question Title

* 39. How would you describe the effect of Piqray on the patient for whom you are caring?

Question Title

* 40. How did treatment with Piqray affect your responsibilities as a caregiver?

T